Conversion of Teva ADSs into Ordinary Shares

These FAQs provide information on the proposed conversion of the outstanding American depositary shares (“ADSs”) of Teva Pharmaceuticals Industries Limited (“Teva” or the “Company”) into Teva ordinary shares, par value NIS 0.10 (the “Ordinary Shares”), and the listing of Teva’s ordinary shares directly on the New York Stock Exchange (“NYSE”) in lieu of the ADSs (the “Conversion”). This document is intended to be read alongside the disclosure in the Company's Form 10-Q filed with the Securities Exchange Commission on July 29, 2026 and any additional disclosure by the Company regarding the Conversion (the “Disclosure”).

The purpose of this document is to provide brief responses to certain questions that shareholders may have regarding the proposed Conversion as set out in the Disclosure. It is for informational purposes only and does not summarize, supplement or replace the information contained in the Disclosure, and shareholders should read the Disclosure before taking any action. This communication does not constitute or form part of, and should not be construed as constituting or forming part of, any offer to sell or issue, any invitation to make an investment in, or any solicitation of any offer to purchase or subscribe for, Teva’s securities.

SECTION 1 – OVERVIEW AND RATIONALE

SECTION 2 – TRADING AND TRANSFERS OF ORDINARY SHARES

SECTION 3 – INFORMATION FOR HOLDERS OF ADSs

SECTION 4 – TAXATION

If you have any additional questions, you may contact Teva’s Investor Relations by sending an email to TevaIR@tevapharm.com.

Forward-Looking Statements

The Company's disclosure regarding the Conversion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause actual results to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “will,” “aim,” “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to implement the mandatory exchange and the delivery of the Ordinary Shares as well as the listing of the Ordinary Shares on the NYSE, which is subject to compliance with applicable law and the rules of the NYSE; the ability of certain intermediaries to implement the contemplated structure for listing the Ordinary Shares on the NYSE, including the Depositary and the Transfer Agent, to implement the contemplated structure for supporting the listing of Ordinary Shares on NYSE, including transitioning books and records to the Transfer Agent; our ability to obtain requisite approval by the NYSE for the listing of the Ordinary Shares; the establishment and maintenance of the contemplated structure with the Transfer Agent and the Depository Trust Company (“DTC”) to support the listing of the Ordinary Shares on the NYSE, including the eligibility of the Ordinary Shares for clearance and custody in the DTC system; and other factors discussed herein and under “Part II, Item 5 – Other Information” including in our Quarterly Report on Form 10-Q for the second quarter of 2026 Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.